Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non Operating Income: 2020-2024

Historic Other Non Operating Income for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Dec 2024 value amounting to $9.5 million.

  • Kiniksa Pharmaceuticals International's Other Non Operating Income rose 27.64% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year increase of 10.02%. This contributed to the annual value of $9.5 million for FY2024, which is 10.77% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Other Non Operating Income stood at $9.5 million for FY2024, which was up 10.77% from $8.5 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Other Non Operating Income registered a high of $9.5 million during FY2024, and its lowest value of $97,000 during FY2021.
  • Moreover, its 3-year median value for Other Non Operating Income was $8.5 million (2023), whereas its average is $6.4 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Other Non Operating Income crashed by 91.45% in 2021 and then skyrocketed by 1,191.75% in 2022.
  • Kiniksa Pharmaceuticals International's Other Non Operating Income (Yearly) stood at $1.1 million in 2020, then plummeted by 91.45% to $97,000 in 2021, then soared by 1,191.75% to $1.3 million in 2022, then soared by 581.88% to $8.5 million in 2023, then climbed by 10.77% to $9.5 million in 2024.